ZA201007958B - Nmda recptor antagonists for the treatment of neuropsychiatric disorders - Google Patents
Nmda recptor antagonists for the treatment of neuropsychiatric disordersInfo
- Publication number
- ZA201007958B ZA201007958B ZA2010/07958A ZA201007958A ZA201007958B ZA 201007958 B ZA201007958 B ZA 201007958B ZA 2010/07958 A ZA2010/07958 A ZA 2010/07958A ZA 201007958 A ZA201007958 A ZA 201007958A ZA 201007958 B ZA201007958 B ZA 201007958B
- Authority
- ZA
- South Africa
- Prior art keywords
- recptor
- nmda
- antagonists
- treatment
- neuropsychiatric disorders
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12709808P | 2008-05-09 | 2008-05-09 | |
| PCT/US2009/043502 WO2009137843A2 (en) | 2008-05-09 | 2009-05-11 | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201007958B true ZA201007958B (en) | 2011-07-27 |
Family
ID=41265475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/07958A ZA201007958B (en) | 2008-05-09 | 2010-11-05 | Nmda recptor antagonists for the treatment of neuropsychiatric disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110160223A1 (https=) |
| EP (1) | EP2296658A4 (https=) |
| JP (1) | JP2011520815A (https=) |
| KR (1) | KR20110016891A (https=) |
| CN (1) | CN102762207A (https=) |
| AU (1) | AU2009244082A1 (https=) |
| BR (1) | BRPI0912362A2 (https=) |
| CA (1) | CA2722776A1 (https=) |
| CO (1) | CO6341558A2 (https=) |
| EA (1) | EA020339B1 (https=) |
| IL (1) | IL208895A0 (https=) |
| MX (1) | MX2010012186A (https=) |
| NZ (1) | NZ589764A (https=) |
| SG (1) | SG195568A1 (https=) |
| WO (1) | WO2009137843A2 (https=) |
| ZA (1) | ZA201007958B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2788656A1 (en) | 2010-02-16 | 2011-08-25 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
| CA2848212C (en) | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2013170072A2 (en) * | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| JP6345651B2 (ja) * | 2012-05-09 | 2018-06-20 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ヘテロアリール化合物及びその使用方法 |
| US8974365B2 (en) * | 2012-11-25 | 2015-03-10 | Steven Richard Devore Best | Treatment of thalamocortical dysrhythmia |
| PT2968369T (pt) | 2013-03-13 | 2018-12-05 | Sage Therapeutics Inc | Esteroides neuroativos e métodos para o seu uso |
| WO2014210456A1 (en) | 2013-06-28 | 2014-12-31 | Emory University | Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2963938C (en) * | 2014-10-07 | 2023-10-24 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| WO2016100940A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| EP3828194B1 (en) | 2015-07-06 | 2025-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE071964T2 (hu) | 2015-07-06 | 2025-10-28 | Sage Therapeutics Inc | Oxiszterolok és alkalmazási eljárásaik |
| CA2991311C (en) * | 2015-07-06 | 2025-05-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND THEIR METHODS OF USE |
| US10583171B2 (en) | 2015-11-30 | 2020-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | NMDAR antagonists for the treatment of diseases associated with angiogenesis |
| SMT202200300T1 (it) | 2016-04-01 | 2022-09-14 | Sage Therapeutics Inc | Ossisteroli e relativi metodi d'uso |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| KR20230051723A (ko) | 2016-10-18 | 2023-04-18 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| WO2019071394A1 (zh) * | 2017-10-09 | 2019-04-18 | 华南农业大学 | 一种抗白色念珠菌的新型化合物及其制备方法和应用 |
| US11981652B2 (en) | 2018-03-28 | 2024-05-14 | Emory University | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor |
| BR112020023882A2 (pt) | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| CN114539129B (zh) * | 2020-11-18 | 2023-06-09 | 上海中医药大学附属龙华医院 | 烯丙胺类双功能化合物及其用途 |
| CA3230601A1 (en) * | 2021-09-02 | 2023-03-09 | Dennis Liotta | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2960178D1 (en) * | 1978-06-06 | 1981-04-09 | Hoechst Ag | New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation |
| DE2824677A1 (de) * | 1978-06-06 | 1979-12-20 | Hoechst Ag | Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung |
| JPS55162774A (en) * | 1979-06-06 | 1980-12-18 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JPS5646812A (en) * | 1979-09-27 | 1981-04-28 | Otsuka Pharmaceut Co Ltd | Central nervous system depressant |
| JPS5649361A (en) * | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JPS5649362A (en) * | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Thiocarbostyril derivative |
| JPS579769A (en) * | 1980-06-23 | 1982-01-19 | Otsuka Pharmaceut Co Ltd | 2-benzimidazolinone derivative |
| JPS58203968A (ja) * | 1982-05-21 | 1983-11-28 | Otsuka Pharmaceut Co Ltd | イソカルボスチリル誘導体 |
| DE3442570A1 (de) * | 1984-11-22 | 1986-05-22 | Hoechst Ag, 6230 Frankfurt | Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere |
| JPS62252783A (ja) * | 1986-02-13 | 1987-11-04 | ワ−ナ−−ランバ−ト・コンパニ− | ベンズ複素環式化合物 |
| GB9005318D0 (en) * | 1990-03-09 | 1990-05-02 | Isis Innovation | Antiarrhythmic agents |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| CA2276373C (en) * | 1997-10-31 | 2010-01-12 | Suntory Limited | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| US7022882B2 (en) * | 2000-10-06 | 2006-04-04 | The Regents Of The University Of California | NMDA receptor channel blocker with neuroprotective activity |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| DE10248925A1 (de) * | 2002-10-15 | 2004-04-29 | Proteosys Ag | Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität |
| MXPA05012325A (es) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Procedimiento para potenciar la cognicion usando zipirasidona. |
| EP2260844A1 (en) * | 2003-05-27 | 2010-12-15 | Merz Pharma GmbH & Co. KGaA | Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders |
| HUP0401526A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use |
| WO2006023957A1 (en) * | 2004-08-23 | 2006-03-02 | Emory University | Improved selection of-ph dependent compounds for in vivo therapy |
| CA2614833A1 (en) * | 2005-07-12 | 2007-01-18 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 2, 3-disubstituted tropanes for the treatment of disorders of sexual desire |
| AR055203A1 (es) * | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2008020306A2 (en) * | 2006-08-18 | 2008-02-21 | Pfizer Products Inc. | Isoindole derivatives |
| EA201070077A1 (ru) * | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
-
2009
- 2009-05-11 JP JP2011508724A patent/JP2011520815A/ja active Pending
- 2009-05-11 CN CN2009801184245A patent/CN102762207A/zh active Pending
- 2009-05-11 BR BRPI0912362A patent/BRPI0912362A2/pt not_active IP Right Cessation
- 2009-05-11 AU AU2009244082A patent/AU2009244082A1/en not_active Abandoned
- 2009-05-11 SG SG2013077359A patent/SG195568A1/en unknown
- 2009-05-11 NZ NZ589764A patent/NZ589764A/xx not_active IP Right Cessation
- 2009-05-11 MX MX2010012186A patent/MX2010012186A/es not_active Application Discontinuation
- 2009-05-11 EP EP09743829.5A patent/EP2296658A4/en not_active Withdrawn
- 2009-05-11 CA CA2722776A patent/CA2722776A1/en not_active Abandoned
- 2009-05-11 WO PCT/US2009/043502 patent/WO2009137843A2/en not_active Ceased
- 2009-05-11 EA EA201071291A patent/EA020339B1/ru not_active IP Right Cessation
- 2009-05-11 KR KR1020107025739A patent/KR20110016891A/ko not_active Ceased
-
2010
- 2010-10-24 IL IL208895A patent/IL208895A0/en unknown
- 2010-11-02 US US12/938,138 patent/US20110160223A1/en not_active Abandoned
- 2010-11-05 ZA ZA2010/07958A patent/ZA201007958B/en unknown
- 2010-11-16 CO CO10143058A patent/CO6341558A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA020339B1 (ru) | 2014-10-30 |
| EP2296658A4 (en) | 2014-01-15 |
| WO2009137843A2 (en) | 2009-11-12 |
| EP2296658A2 (en) | 2011-03-23 |
| CO6341558A2 (es) | 2011-11-21 |
| CA2722776A1 (en) | 2009-11-12 |
| BRPI0912362A2 (pt) | 2015-10-06 |
| IL208895A0 (en) | 2011-01-31 |
| NZ589764A (en) | 2012-10-26 |
| SG195568A1 (en) | 2013-12-30 |
| AU2009244082A1 (en) | 2009-11-12 |
| EA201071291A2 (ru) | 2011-04-29 |
| US20110160223A1 (en) | 2011-06-30 |
| CN102762207A (zh) | 2012-10-31 |
| JP2011520815A (ja) | 2011-07-21 |
| EA201071291A3 (ru) | 2014-02-28 |
| KR20110016891A (ko) | 2011-02-18 |
| MX2010012186A (es) | 2011-02-22 |
| WO2009137843A9 (en) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201007958B (en) | Nmda recptor antagonists for the treatment of neuropsychiatric disorders | |
| ZA200905012B (en) | Process for the preparation of certain substituted sulfimines | |
| ZA201007446B (en) | Tungsten rhenium compounds and composites and methods for forming the same | |
| PL2297073T3 (pl) | Sposób wytwarzania 2, 3, 3, 3-trifluoropropenu | |
| ZA201102640B (en) | Use of scyllo-inositols for the treatment of macular degeneration-related disorders | |
| EP2312947A4 (en) | TRPV4 Antagonist | |
| PL2151428T3 (pl) | Nowy sposób syntezy agomelatyny | |
| ZA200907191B (en) | Process for the preparation of gefitiib | |
| IL208792A0 (en) | Process for the preparation of amides | |
| IL208611A0 (en) | Device and process for the formation of microdepositions | |
| ZA201005341B (en) | Methods for inhibiting angiogenesis using egfl8 antagonists | |
| EG26332A (en) | Process for the preparation of benzonoprons | |
| IL200380A0 (en) | Mineralcorticoid receptor antagonists for the treatment of endometriosis | |
| SI2151429T1 (sl) | Postopek za pripravo agomelatina | |
| SI2225232T1 (sl) | Postopek za pripravo substituiranih 1,3-oksatiolanov | |
| EP2323989A4 (en) | METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS | |
| GB2469980A8 (en) | Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof. | |
| ZA201000802B (en) | Process for the preparation of alfuzosin hydrochloride | |
| IL202475A0 (en) | Process for the preparation of aldehydes | |
| IL211996A0 (en) | Process for the preparation of substituted phenylalanines | |
| ZA201202150B (en) | [1,4]-benzodiazepines as vasopressin v2 receptor antagonists | |
| ZA201005337B (en) | Treatment for ocular-related disorders | |
| IL208868A0 (en) | Processes for the preparation of amides | |
| HK1155643A (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| IL211382A0 (en) | Process for the preparation of ethanedinitrile |